[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,64,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634374","safety-and-efficacy-of-ct0494bcp-in-participants-with-advanced-gastricesophagogastric-junction-adenocarcinoma-100634374",false,"NCT07538856","Safety and Efficacy of CT0494BCP in Participants With Advanced Gastric\u002FEsophagogastric Junction Adenocarcinoma","A Clinical Trial Exploring the Safety and Efficacy of CT0494BCP CAR-T Cell Injection in Participants With Advanced Gastric\u002FEsophagogastric Junction Adenocarcinoma","Inclusion Criteria:\n\nVolunteer to participate in the clinical trial; I fully understand and are informed of this trial and sign the informed consent form; Willing to follow and able to complete all trial procedures; Age 18-70 years (inclusive), male or female; Participants with pathologically confirmed advanced gastric\u002Fesophagogastric junction adenocarcinoma; Failed at least second-line treatment (if the first-line treatment includes three drugs including taxanes \\[or anthracyclines\\], platinum and fluoropyrimidines, the participants can also be enrolled into the trial as eligible as assessed by the investigator); Participant's tumor tissue sample is CLDN18.2 positive by immunohistochemistry (IHC) staining (expression intensity ≥ 2 + and% positive tumor cells ≥ 40%); Estimated survival \\> 12 weeks; Measurable tumor lesions according to RECIST v1.1; ECOG performance status 0 \\~ 1;\n\nUnless otherwise specified, participants should meet the following criteria before clearing the lymphoma (local laboratory results that do not meet the following criteria are allowed to perform a re-examination within one week; if they still do not meet the criteria, they cannot clear the lymphoma):\n\nBlood routine: neutrophil (NE) ≥ 1.5 × 109\u002FL, lymphocyte (LY) 0.5 × 109\u002FL, platelet (PLT) ≥ 75 × 109\u002FL, hemoglobin (Hb) ≥ 9.0 g\u002FdL (no transfusion, platelet transfusion, cell growth factor \\[except recombinant erythropoietin\\] and other supportive treatment within 14 days before detection); Blood biochemistry: endogenous creatinine clearance ≥ 50 mL\u002Fmin (using Cockcroft-Gault formula), alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) ≤ 2.5 × ULN, total bilirubin ≤ 2 × ULN; Serum lipase and amylase ≤ 2 × ULN; Alkaline phosphatase ≤ 2.5 × ULN; AST, ALT and alkaline phosphatase ≤ 5 × ULN if there is bone metastasis or liver metastasis; Prothrombin time (PT) prolongation ≤ 4 s. 10. Female participants of childbearing potential must have a negative serum pregnancy test at screening and be willing to use a highly effective and reliable method of contraception for 1 year after the last dose of study treatment. The available methods are: bilateral tubal ligation\u002Fbilateral salpingectomy or bilateral tubal occlusion; Or approved oral, injected or implanted hormonal methods of birth control; Or barrier contraception: condom or occlusive cap (diaphragm or cervical\u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository; Male participants who are sexually active with a female of childbearing potential who have not had a vasectomy must agree to use a barrier method of birth control, such as a condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository, or to use a contraceptive method for their partner (see Inclusion Criterion # 10). All men absolutely refrain from donating sperm for 1 year after the last dose of study treatment.\n\nExclusion Criteria:\n\n1. Pregnant or lactating females;\n2. HIV, Treponema pallidum, HCV serology positive (HCV antibody positive but HCV-RNA negative can be included), Epstein-Barr virus (EBV) DNA (plasma or whole blood) positive, cytomegalovirus (CMV) DNA positive;\n3. Any uncontrolled active infection, including but not limited to active tuberculosis, HBV infection (including HBsAg positive, or HBcAb positive with HBV DNA above the lower limit of the laboratory test in our center), and other bacterial, viral or fungal infections requiring drug treatment. Participants who use drugs to prevent infection and can continue the trial as judged by the investigator;\n4. Known HER2-positive (defined as IHC3 +, or IHC2 + with amplification by FISH);\n5. Clinically significant abnormal thyroid function as judged by the investigator (serum thyroid hormone determination includes at least FT3, FT4 and serum thyroid stimulating hormone TSH), but patients with hypothyroidism whose disease is under stable control as assessed by the investigator can enter the trial;\n6. Toxic reactions caused by previous treatment have not recovered to CTCAE v6.0 ≤ Grade 1, except for alopecia and other tolerable events as judged by the investigator or laboratory abnormalities allowed in this trial;\n7. Received anti-tumor treatment for the disease under study within 2 weeks prior to CLL, including but not limited to surgery, systemic chemotherapy (or within 5 half-lives of the drug, whichever is shorter), radiotherapy, intervention, etc., or received anti-PD-(L) 1 monoclonal antibody therapy or CLDN18.2 targeted therapy or other non-marketed clinical trial drugs within 4 weeks prior to CLL (or within 5 half-lives of the drug, whichever is shorter);\n8. Ongoing use of glucocorticoids within 7 days prior to CLL. Recent or current use of inhaled or topical dermal glucocorticoids and physiologic replacement therapy doses of glucocorticoids were not excluded;\n9. Vaccination with live attenuated vaccines within 4 weeks prior to CLL or planned during the trial;\n10. Participants with known active autoimmune disease, including but not limited to psoriasis or rheumatoid arthritis, or other conditions requiring chronic use of immunosuppressive therapy;\n11. Previous allergies to immunotherapy, tocilizumab, cyclophosphamide, fludarabine or nab-paclitaxel and other related drugs, allergies to components of CT0494BCP such as albumin, DMSO or other severe allergies;\n12. Previously received any genetic engineering modified cell therapy (including CAR-T, TCR-T cells, etc.);\n13. Presence of known or suspected central nervous system metastases;\n14. Central type or extensive lung metastasis, or extensive liver metastasis, or extensive bone metastasis;\n15. The longest diameter of a single target lesion \\> 4 cm before CLL (lymph node lesion is short axis);\n16. Participants with high risk of bleeding or perforation, such as deep and large ulcer in primary lesion, or anastomotic recurrence with full-thickness tumor invasion, or tumor lesion invasion into large vessels, as detected by CT\u002FMRI or combined with gastroscopy;\n17. Participants with current unstable or active ulcers, active gastrointestinal bleeding, or a history of major gastrointestinal bleeding within 3 months;\n18. Participants who require anticoagulation therapy such as warfarin or heparin;\n19. Participants who are receiving or anticipate the need to receive long-term antiplatelet therapy during the trial;\n20. Abdominal\u002Fpleural effusion with clinical symptoms or requiring special treatment, such as repeated drainage, abdominal\u002Fpleural drug perfusion, etc. (participants with small amount of ascites\u002Fpleural effusion that can be detected by imaging examination or controllable as assessed by the investigator can be considered for enrollment);\n21. Participants with a history of organ transplantation or who are awaiting organ transplantation;\n22. Participants who have had major surgery or significant trauma within 4 weeks prior to CLL, or anticipate the need for major surgery during the trial;\n23. Other conditions not suitable for participation in this trial as assessed by the investigator prior to CLL, including but not limited to: Poorly controlled diabetes with severe complications, poorly controlled hypertension (blood pressure \\> 160 mmHg\u002F100 mmHg), hypertension requiring vasopressor drugs or symptomatic hypotension, cardiac insufficiency (including left ventricular ejection fraction \\[LVEF\\] \\\u003C 50%), myocardial infarction within the past 6 months, arrhythmia or unstable angina poorly controlled by drug therapy, pulmonary embolism, severe chronic obstructive pulmonary disease, interstitial lung disease, clinically significant abnormal pulmonary function test, gastrointestinal obstruction or perforation within the past 3 months, severe inflammatory state (e.g. Increased neutrophils and\u002For C-reactive protein); Medical discussion with the sponsor is recommended if necessary;\n24. Inability or unwillingness of the participant to comply with the protocol requirements as assessed by the investigator;\n25. Blood oxygen saturation ≤ 95% (finger oxygen detection method is accepted, without oxygen inhalation);\n26. Participant has signs of central nervous system disease or clinically significant abnormal neurological examination results or psychiatric disorders;\n27. Patients with other incurable malignant tumors in the past 3 years or at the same time, except for cervical cancer in situ, skin basal cell carcinoma and other very low-grade tumors.","ALL","18 Years","70 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","To evaluate the safety and tolerability of CT0494BCP following infusion in participants with advanced gastric\u002Fesophagogastric junction adenocarcinoma (G\u002FGEJA) To evaluate preliminary efficacy of CT0494BCP To evaluate the cellular metabolism kinetics of CT0494BCP The investigational drug in this study is CT0494BCP cells, including CT0494 cells and CT7095 cells. Dose escalation will be performed according to the Bayesian optimal interval (BOIN) design principle (refer to the dose escalation principle in Section 4.1 Study Design Description and the flow chart of BOIN design in Figure 2 for details) and dose expansion. In the dose escalation phase, CT0494 cells were tentatively assigned to 3 escalating doses of 3.0 × 108, 4.5 × 108 and 6.0 × 108, respectively, and CT7095 cells were tentatively assigned to 2 escalating doses of 1.5 × 108 and 3.0 × 108, respectively. If the exploratory dose is not identified as a possible recommended dose (RD), a possible RD may be explored by escalating to a higher dose or tapering to a lower dose at the discretion of the investigator and sponsor in consultation. Dose groups, number of subjects per dose group, and other escalation or de-escalation decisions may be adjusted during the study based on available data.",[25,26],"Gastric","Gastric \u002F Gastroesophageal Junction Adenocarcinoma",[28],"CT0494BCP","NOT_YET_RECRUITING","2026-04-13",{"date":32,"type":33},"2026-04-20","ACTUAL",{"date":35,"type":21},"2026-04",{"date":37,"type":21},"2028-03",{"name":39,"class":40},"Beijing GoBroad Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":5},"100455038","trans-pacific-multicenter-collaborative-study-of-minimally-invasive-proximal-versus-total-gastrectomy-for-proximal-gastric-and-gastroesophageal-junction-cancers-100455038","NCT05205343","Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers","Inclusion:\n\n1. Able to speak and read English, Spanish, Japanese or Korean\n2. Participants with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention\n3. Age ≥ 18\n\nExclusion:\n\n1. Participants with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract\n2. Participants with known narcotic dependence, with average daily dose \\> 5 mg oral morphine equivalent\n3. Participants deemed unable to comply with study and\u002For follow-up procedures, at investigators' discretion\n4. Participants who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)",{"count":49,"type":21},20,"To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.",[52,25,53],"Gastrostomy","GastroEsophageal Cancer","RECRUITING","2026-02-02",{"date":57,"type":33},"2026-02-04",{"date":59,"type":33},"2022-05-11",{"date":61,"type":21},"2026-05-31",{"name":63,"class":40},"M.D. Anderson Cancer Center",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":41},"100569589","to-evaluate-the-best-metric-for-inspection-time-during-a-diagnostic-andor-surveillance-upper-gastrointestinal-endoscopy-age--18-years-informed-consent-between-total-inspection-time-versus-withdrawal-time-for-the-identification-of-malignant-lesions-100569589","NCT06696209","To Evaluate the Best Metric for Inspection Time During a Diagnostic and\u002For Surveillance Upper Gastrointestinal Endoscopy (Age ≥ 18 Years, Informed Consent), Between Total Inspection Time Versus Withdrawal Time, for the Identification of Malignant Lesions","Analysis of Withdrawal Time in Upper Gastrointestinal Endoscopy as Procedure Time: a Randomised, Parallel, Double-blinded, Multicenter, International Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnostic or surveillance upper gastrointestinal endoscopy for premalignant conditions\n* Informed consent for the execution of the upper gastrointestinal endoscopy and participation in the study\n\nExclusion Criteria:\n\n* Previous esophagus, stomach, or duodenum surgery\n* Known or suspected neoplasia\n* Therapeutic procedure (polypectomy, argon plasma coagulation, hemostasis, others)",true,{"count":73,"type":21},1290,"INTERVENTIONAL",[76],"NA","Gastric cancer is the fifth cause of cancer-related mortality worldwide. Gastric carcinogenesis involves the progression from premalignant conditions such as atrophic gastritis and intestinal metaplasia to premalignant lesions like dysplasia, and ultimately carcinoma. Most diagnoses of gastric cancer are made at advanced stages, with a five-year relative survival rate of 36%. Therefore, early detection of premalignant conditions and lesions is crucial, as it allows for timely surveillance and treatment, which can improve patient survival.\n\nUpper gastrointestinal endoscopy (UGE) is the first-line examination for diagnosing upper gastrointestinal tract pathology, particularly oncological conditions. The European Society of Gastrointestinal Endoscopy (ESGE) and the United European Gastroenterology (UEG) have established that UGE quality is a priority, identifying specific quality parameters, such as the duration of the procedure, which is the most extensively studied parameter.\n\nAccording to ESGE recommendations, all UGE reports should include the procedure time (goal: ≥90% of reports), which should be seven minutes or longer for surveillance of intestinal metaplasia. This time threshold follows a study that established a causal relationship between longer procedures (≥ seven minutes) and a higher detection rate of premalignant gastric conditions and lesions. Subsequent observational studies have generally shown that setting a minimum procedure time increases the detection rate of lesions.\n\nThe definition of procedure time varies between studies, being described as the time from intubation to extubation, but also as the time for withdrawing the endoscope from the second portion of the duodenum (D2) to extubation, also known as withdrawal time.\n\nThe hypothesis under study is that a better definition of the most appropriate time for a diagnostic UGE could standardize reports, improve malignant lesion detection rates, and reduce the rate of undiagnosed cancers, without any additional risk to patients.\n\nExisting studies have been retrospective or comparative between different temporal cohorts, with no prospective or randomised comparative studies, nor any studies comparing the two existing metrics. Therefore, the aim of this study is to evaluate the best metric for inspection time during a diagnostic and\u002For surveillance UGE, between total inspection time versus withdrawal time, for the identification of malignant lesions.",[79,80,25,81,82],"Premalignant Conditions","Malignant Lesions","Esophageal","Duodenal","2025-06-01",{"date":85,"type":33},"2025-06-04",{"date":87,"type":33},"2025-03-07",{"date":89,"type":21},"2026-01-01",{"name":91,"class":40},"Portuguese Oncology Institute, Coimbra",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":71,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":74,"phases":102,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":118,"leadSponsor":120,"locationsCount":41},"100525201","phase-2-chemotherapy-sequential-tislelizumab-after-radical-resection-in-patients-with-dmmrmsi-h-or-polepold1-mutations-100525201","NCT06118658","Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR\u002FMSI-H or POLE\u002FPOLD1 Mutations","A Single-arm, Open, Multicenter Phase II Study of Chemotherapy-sequential Tislelizumab Adjuvant Therapy After Radical Resection in Patients With Gastric or Colorectal Adenocarcinoma With dMMR\u002FMSI-H or POLE\u002FPOLD1 Mutations","Inclusion Criteria:\n\n1.Be able to understand and voluntarily sign a written informed consent, which must be signed prior to performing the specified study procedure required for the study 2.Age and gender: ≥18 years old and≤75 years old, both men and women. 3.dMMR\u002FMSI-H or POLE\u002FPOLD1 gene mutation was confirmed by immunohistochemical PCR or NGS 4.0-1 physical fitness score by the Eastern United States Cancer Collaboration (ECOG)。 5. Expected survival is 12 weeks 6.Radical gastrectomy or enterectomy, including open surgery or laparoscopic surgery, to achieve R0 resection (no residual cancer at the margin) 7.According to the American Joint Committee on Cancer AJCC 8th Edition cancer stage, it was confirmed by histopathology as gastric adenocarcinoma or esophagogastric junction adenocarcinoma or intestinal adenocarcinoma, and the postoperative pathological stage of gastric adenocarcinoma or esophagogastric junction adenocarcinoma was stage III; Patients with postoperative pathological stage of intestinal cancer T1-3N2M0 or T4N+M0 8.No metastasis or recurrence was determined based on images taken after surgery and within the first 28 days of randomization 9. Subjects are required to provide sufficient FFPE tumor tissue specimens or sections for relevant testing 10.The functions of important organs must meet the following requirements:\n\n1. Hematological system（No blood component or cell growth factor was used to support treatment within 7 days prior to the start of study therapy）:\n\n   Neutrophil count≥1.5×10\\^9\u002FL; Platelet count≥100×10\\^9\u002FL; Hemoglobin≥90g\u002FL;\n2. Liver function： Serum albumin≥28g\u002FL; Total bilirubin (TBI)≤1.5×ULN; Alanine aminotransferase (ALT)≤3×ULN Aspartate aminotransferase (AST)≤2.5×ULN\n3. Renal function:\n\n   Serum creatinine ≤1.5×ULN Calculated creatinine clearance≥50 mL\u002Fmin (using the Cockcroft-Gault formula); Female: CrCl = (140- age in years) × weight in kg × 0.85 72 × serum creatinine in mg\u002F dL\n\n   Male: CrCl = (140- age in years) × weight in kg × 1.00 72 × serum creatinine in mg\u002F dL\n4. Coagulation function:\n\n   Subjects not receiving anticoagulation therapy: INR or APTT ≤ 1.5×ULN;\n5. Cardiac function: Left ventricular ejection fraction (LVEF)≥ 50 10. Fertile female subjects must undergo a urine or serum pregnancy test within 3 days prior to the first dosing (if the urine pregnancy test result is not confirmed negative, a serum pregnancy test is required, depending on the serum pregnancy result), and the result is negative If a fertile female subject has sex with an unsterilized male partner, the subject must use a highly effective contraceptive method since screening and must consent to continued use of the contraceptive method for 120 days after the last administration of the study drug; Whether to stop contraception after this time point should be discussed with the investigator 11.If an unsterilized male subject has sex with a fertile female partner, the subject must use an effective contraceptive method from the beginning of screening until the 120th day after the last dose; Whether to stop contraception after this time point should be discussed with the investigator.\n\n12.Subjects were willing and able to comply with the schedule for visiting treatment protocol laboratory tests and other study requirements.\n\nExclusion Criteria:\n\n1. Subjects with other malignancies in the 5 years prior to enrolment do not exclude subjects with other malignancies that have been cured by local treatment, such as basal or skin squamous cell carcinoma superficial bladder cancer cervix or breast carcinoma in situ\n2. Have received non-surgical treatment for gastric\u002Fesophagogastric junction\u002Fbowel cancer (e.g., radiotherapy, chemotherapy and hormone therapy)\n3. Liver peritoneum or distant metastasis\n4. Inability to take medications orally\n5. Unrelieved postoperative complications during screening (such as postoperative infection, suture rupture, gastrointestinal bleeding, pancreatic leakage, etc.)\n6. There are chemotherapy drugs contraindicated in this study and any group of adjuvant therapy regiments specified in the regimen cannot be accepted\n7. People with active autoimmune diseases that have required systemic treatment within the past two years (such as treatment with disease-modifying drugs, corticosteroids, immunosuppressants) and replacement therapy (such as insulin thyroxine or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) are not considered a systemic treatment\n8. There is a pleural, pericardial or abdominal effusion that is clinically symptomatic, requires diuretic treatment and\u002For requires repeated drainage.\n9. There are active or recurrent inflammatory gastrointestinal diseases (such as Crohn's disease ulcerative colitis hemorrhagic enteritis chronic diarrhea, etc.)\n10. A history of myocarditis and cardiomyopathy with malignant arrhythmias.Unstable angina pectoris, myocardial infarction, congestive heart failure (grade 2 or higher according to the New York Heart Association Functional Scale), or vascular disease (such as an aortic aneurysm at risk of rupture) requiring hospitalization in the 12 months prior to initial administration,Or other heart damage that may affect the safety evaluation of the investigational drug (e.g., poorly controlled arrhythmias, myocardial ischemia)\n11. Medically difficult to control hypertension (systolic blood pressure ≥150mmHg and\u002For diastolic blood pressure ≥100mmHg) (based on an average of ≥2 measurements).\n12. Uncontrolled diabetes.\n13. Peripheral neuropathy ≥ grade 2.\n14. Severe infection within 4 weeks prior to initial dosing, including but not limited to comorbidized sepsis or severe pneumonia requiring hospitalization; Active infections that have received systemic anti-infective therapy within 2 weeks prior to initial dosing (excluding antiviral therapy for hepatitis B or C)\n15. Known active tuberculosis (TB), suspected active TB subjects need to undergo clinical examination to rule out; Known active syphilis infection\n16. Subjects with current active hepatitis B (HBsAg positive with more than 2000 copies \u002Fml(500 IU\u002Fml) of HBV-DNA or higher than the lower limit of detection, whichever is higher), for subjects with hepatitis B, are required to receive anti-HBV therapy during the study treatment; Active hepatitis C subjects (HCV antibody positive with HCV-RNA levels above the lower limit of detection)\n17. History of immune deficiency; HIV antibody test positive; Systemic corticosteroid hormones or other immunosuppressants are currently being used on a long-term basis\n18. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation\n19. Prior treatment with PD-1 receptor or its ligand PD-L1 or cytotoxic T lymphocyte-associated protein 4(CTLA-4) receptor\n20. Known allergy to any component of any investigational drug; There is a known history of severe hypersensitivity to other monoclonal antibodies\n21. Inactivated vaccines are allowed if a live or attenuated vaccine has been administered in the 30 days prior to the first dose, or if a live or attenuated vaccine is planned to be administered during the study\n22. Known history of mental illness substance abuse alcohol or drugs\n23. Pregnant or lactating women\n24. The presence of any past or current abnormality in laboratory tests for treatment of disease that may confuse the study results, affect the subject's full participation in the study, or participation in the study may not be in the subject's best interest\n25. Local or systemic disease caused by non-malignant tumors; Or disease or symptoms secondary to the tumor and can lead to higher medical risk and\u002For uncertainty in the evaluation of survival\n26. Any condition that the investigator believes may cause subjects to receive the study drug treatment to be at risk of interfering with the evaluation of the study drug, or affecting the interpretation of the study results","75 Years",{"count":101,"type":21},30,[103],"PHASE2","Objective of this study to evaluate 1-year disease-free survival in patients with dMMR\u002FMSI-H or POLE\u002FPOLD1 gene mutations with gastric or esophagus-gastric junctional adenocarcinoma or colorectal adenocarcinoma after chemotherapy-sequential tiralizumab adjuvant radical resection (based on RECIST v1.1 criteria).",[25,106],"Colorectal Adenocarcinoma",[108,109,110,111,112,113],"radical resection","adjuvant therapy","gastric","colorectal adenocarcinoma","esophagogastric junction adenocarcinoma","dMMR\u002FMSI-H or POLE\u002FPOLD1 mutations","2023-11-01",{"date":116,"type":33},"2023-11-07",{"date":114,"type":21},{"date":119,"type":21},"2026-12-31",{"name":121,"class":40},"China Medical University, China"]